1. Introduction {#sec1-nutrients-12-02218}
===============

Cardiovascular diseases (CVDs) are characterized by any disorders relating to the heart or blood vessels \[[@B1-nutrients-12-02218]\], including coronary heart disease (CHD), cerebrovascular disease, stroke, peripheral vascular disease, rheumatic and congenital heart diseases, and venous thromboembolism \[[@B2-nutrients-12-02218]\]. It has been reported that the burden of CVDs has remained high over the past decades, with 75% of overall CVD deaths occurring in low- to middle-income countries \[[@B3-nutrients-12-02218]\]. In general, the prevalence of CVDs is closely related to various risk factors, such as hypertension, overweight and obesity, dyslipidemia, and diabetes \[[@B4-nutrients-12-02218],[@B5-nutrients-12-02218]\]. According to recent guidelines of the American College of Cardiology/American Heart Association (ACC/AHA) regarding the primary prevention of CVD, individuals aged 40 to 75 years with diabetes mellitus and low-density lipoprotein-cholesterol (LDL-C) ≥70 mg/dL or those with hypercholesterolemia (LDL-C ≥190 mg/dL) regardless of CVD risk are recommended with moderate to high-intensity statins \[[@B6-nutrients-12-02218],[@B7-nutrients-12-02218]\]. Additionally, according to the European Society of Cardiology and the European Atherosclerosis Society (ESC/EAS) guidelines, high-risk individuals with LDL-C ≥190 mg/dL or triglyceride (TG) \>200 mg/dL are also suggested with statin therapy \[[@B8-nutrients-12-02218],[@B9-nutrients-12-02218]\].

Although findings from a meta-analysis of 19 randomized controlled trials (RCTs) showed the protective effect of statins on CVD events among a high-risk population compared with a placebo or non-statin interventions \[[@B10-nutrients-12-02218]\], updated evidence from recent RCTs is required. In addition, a recent meta-analysis of 13 RCTs found marine omega-3 supplementation to be associated with a decreased risk of CVD events in a dose-response manner \[[@B11-nutrients-12-02218]\], though the analysis was restricted to only certain RCTs \[[@B12-nutrients-12-02218],[@B13-nutrients-12-02218],[@B14-nutrients-12-02218],[@B15-nutrients-12-02218],[@B16-nutrients-12-02218]\]. Overall, the pairwise effects of statins and omega-3 supplementation on CVD prevention have not been investigated. Therefore, this study aims to systematically summarize current evidence of the effect of statins and omega-3 supplementation through a meta-analysis and to elucidate the comparative efficacy of statins and omega-3 supplementation in the prevention of cardiovascular events through a network meta-analysis (NMA) of RCTs.

2. Methods {#sec2-nutrients-12-02218}
==========

2.1. Literature Search {#sec2dot1-nutrients-12-02218}
----------------------

We searched RCTs from previously published systematic reviews or meta-analyses of statin use or omega-3 supplementation in PubMed from its inception to January 2020. The search keywords were statin (statins or \*statin), omega-3 (fish oil) supplementation (supplement or supplements), cardiovascular disease (cardiovascular diseases), systematic review, and meta-analysis.

2.2. Eligibility Criteria {#sec2dot2-nutrients-12-02218}
-------------------------

Two review authors (T.H. and J.K.) independently performed the search and assessed the eligibility of studies. We included RCTs reporting the comparative efficacy of a statin versus a statin, a statin versus an omega-3 supplementation, a statin versus a control, or an omega-3 supplementation versus a control for the prevention of total CVD, CHD, myocardial infarction (MI), and stroke. We considered seven currently available HMG-CoA reductase inhibitors: atorvastatin, fluvastatin, lovastatin, pitavastatin, pravastatin, rosuvastatin, and simvastatin.

The following exclusion criteria were used: outcome data or full text not available; follow-up duration less than 1 year; source of omega-3 from dietary intake; or placebo containing omega-6. Studies investigating the effect of a high dose compared with a low dose of the same treatment or comparing the intervention with an active drug were also excluded. For each RCT, the following information was extracted: study name, publication year, mean or median age (years) and follow-up time (years); the percentages of subjects with a history of MI, hypertension, diabetes, and smoking; treatment name, sample size, number of each cardiovascular event, and baseline and achieved serum concentrations of total cholesterol (TC), TG, high-density lipoprotein cholesterol (HDL-C), and LDL-C for each treatment arm.

2.3. Statistical Analysis {#sec2dot3-nutrients-12-02218}
-------------------------

We first investigated the association between statins and omega-3 supplementation and the risk of total CVD, CHD, MI, and stroke in a meta-analysis of direct evidence. Subgroup analyses for statins and sensitivity analyses using both fixed-effect and random-effects models were also performed. The Higgins I^2^ metric \[[@B17-nutrients-12-02218]\] was used to measure heterogeneity across individual studies. Additionally, we performed meta-regression analysis to determine whether the effects of total statins and omega-3 supplementation on cardiovascular event prevention were modulated due to their lipid-lowering effect. In particular, the lipid lowering effect was identified as the absolute difference (mg/dL) in lipid changes (= achieved level---baseline level) between the intervention arm and the comparison arm. Weighted mean difference (WMD) and 95% CI were calculated for the pooled effect of statins and omega-3 supplementation on LDL-C reduction. We further applied a generalized additive model using the 'mgcv' package \[[@B18-nutrients-12-02218]\] to access the non-linear association between cardiovascular event prevention effect and LDL-C reduction in statins and omega-3 supplementation arm separately.

Relative risks (RRs) and 95% confidence intervals (CIs) for the comparative efficacy of statins, omega-3 supplementation, and control were computed in the NMA. As the prior probability was not established in the study hypothesis, we performed the NMA with the frequentist approach to combine direct and indirect evidence \[[@B19-nutrients-12-02218]\]. A funnel plot was utilized to assess publication bias \[[@B20-nutrients-12-02218]\], and a contribution plot was applied to examine the influence of direct estimates on network summary effects \[[@B21-nutrients-12-02218]\]. Stata SE version 14.0 (StataCorp, College Station, TX, USA) and R software (R Foundation for Statistical Computing, Vienna, Austria) (version 3.5.2) were used for all statistical analyses.

3. Results {#sec3-nutrients-12-02218}
==========

3.1. Study Characteristics {#sec3dot1-nutrients-12-02218}
--------------------------

In total, 1259 potentially relevant records were assessed ([Figure 1](#nutrients-12-02218-f001){ref-type="fig"}); 11 meta-analyses \[[@B11-nutrients-12-02218],[@B22-nutrients-12-02218],[@B23-nutrients-12-02218],[@B24-nutrients-12-02218],[@B25-nutrients-12-02218],[@B26-nutrients-12-02218],[@B27-nutrients-12-02218],[@B28-nutrients-12-02218],[@B29-nutrients-12-02218],[@B30-nutrients-12-02218],[@B31-nutrients-12-02218]\] were reviewed, and eligible RCTs were extracted. Of the 387 extracted RCTs, 324 were excluded for the following reasons: unrelated topic (*N* = 82), insufficient data (*N* = 4), duplicate publication or population overlap (*N* = 115), inappropriate treatment (*N* = 19), non-target outcome (*N* = 51), other study design (*N* = 10), external source of omega-3 (*N* = 15), and duration of follow-up (*N* = 28). Ultimately, 45 RCTs of statins and 18 RCTs of omega-3 supplementation involving 264,516 adults were included in the meta-analysis and NMA \[[@B12-nutrients-12-02218],[@B13-nutrients-12-02218],[@B14-nutrients-12-02218],[@B15-nutrients-12-02218],[@B16-nutrients-12-02218],[@B32-nutrients-12-02218],[@B33-nutrients-12-02218],[@B34-nutrients-12-02218],[@B35-nutrients-12-02218],[@B36-nutrients-12-02218],[@B37-nutrients-12-02218],[@B38-nutrients-12-02218],[@B39-nutrients-12-02218],[@B40-nutrients-12-02218],[@B41-nutrients-12-02218],[@B42-nutrients-12-02218],[@B43-nutrients-12-02218],[@B44-nutrients-12-02218],[@B45-nutrients-12-02218],[@B46-nutrients-12-02218],[@B47-nutrients-12-02218],[@B48-nutrients-12-02218],[@B49-nutrients-12-02218],[@B50-nutrients-12-02218],[@B51-nutrients-12-02218],[@B52-nutrients-12-02218],[@B53-nutrients-12-02218],[@B54-nutrients-12-02218],[@B55-nutrients-12-02218],[@B56-nutrients-12-02218],[@B57-nutrients-12-02218],[@B58-nutrients-12-02218],[@B59-nutrients-12-02218],[@B60-nutrients-12-02218],[@B61-nutrients-12-02218],[@B62-nutrients-12-02218],[@B63-nutrients-12-02218],[@B64-nutrients-12-02218],[@B65-nutrients-12-02218],[@B66-nutrients-12-02218],[@B67-nutrients-12-02218],[@B68-nutrients-12-02218],[@B69-nutrients-12-02218],[@B70-nutrients-12-02218],[@B71-nutrients-12-02218],[@B72-nutrients-12-02218],[@B73-nutrients-12-02218],[@B74-nutrients-12-02218],[@B75-nutrients-12-02218],[@B76-nutrients-12-02218],[@B77-nutrients-12-02218],[@B78-nutrients-12-02218],[@B79-nutrients-12-02218],[@B80-nutrients-12-02218],[@B81-nutrients-12-02218],[@B82-nutrients-12-02218],[@B83-nutrients-12-02218],[@B84-nutrients-12-02218],[@B85-nutrients-12-02218],[@B86-nutrients-12-02218],[@B87-nutrients-12-02218],[@B88-nutrients-12-02218]\].

[Table 1](#nutrients-12-02218-t001){ref-type="table"} summarizes the characteristics of the included RCTs. The median age of the participants was 62.6 years, and the follow-up duration was 3.7 years; the rates of a history of MI, hypertension, diabetes, and smoking were 24.8%, 50.6%, 18.9%, and 38.6%, respectively. Additionally, the lipid profiles of TC, TG, HDL-C, and LDL-C of study participants from individual RCTs at baseline and differences in the change of serum lipid concentrations during the follow-up are presented in [Table 2](#nutrients-12-02218-t002){ref-type="table"}.

3.2. Meta-Analysis of Direct Estimates {#sec3dot2-nutrients-12-02218}
--------------------------------------

In comparison with the control group, the pooled direct estimates of statins or omega-3 supplementation and the risk of CVD events are summarized in [Table 3](#nutrients-12-02218-t003){ref-type="table"}. Overall, the levels of significant findings were equivalent in both the fixed-effects and random-effect models, except for the association between atorvastatin or rosuvastatin and the risk of stroke. The total statin and omega-3 groups exhibited reduced risks of total CVD (RR = 0.89, 95% CI = 0.85--0.94), CHD (RR = 0.81, 95% CI = 0.75--0.89), MI (RR = 0.78, 95% CI = 0.78--0.85), and stroke (RR = 0.91, 95% CI = 0.85--0.98).

In subgroup analysis by statins, total statins were associated with decreased risks of total CVD, CHD, MI, and stroke, with RRs (95% CIs) of 0.81 (0.76--0.86), 0.70 (0.62--0.77), 0.69 (0.61--0.78), and 0.85 (0.79--0.82), respectively. Individually, atorvastatin and pravastatin had significant effects on all outcomes. Furthermore, rosuvastatin was associated with significantly reduced risks of CHD and MI, and lovastatin was associated with a significant risk reduction in total CVD. Fewer stroke events occurred in the simvastatin group than in the control group, and fluvastatin was observed to reduce total CVD. Moreover, omega-3 supplementation was associated with a 19% reduced risk of CHD (RR = 0.81, 95% CI = 0.75--0.89) and an 11% reduced risk of MI (RR = 0.89, 95% CI = 0.80--0.99).

The meta-regression coefficients for the association between the lipid-lowering effect and risk reduction of cardiovascular events are presented in [Table 4](#nutrients-12-02218-t004){ref-type="table"}. The size of TC reduction achieved with overall statins and omega-3 supplementation was significantly associated with the size of total CVD and CHD reduction effect, with coefficients (*p*-values) of 0.0046 (\<0.001) and 0.0042 (0.047), respectively. Additionally, total CVD and CHD reduction effect might be driven by per unit change in LDL-C level, with decreases of 0.0034 (*p* = 0.004) and 0.0044 (*p* = 0.047) in log (RRs) for total CVD and CHD per 1 mg/dL LDL-C lowering effect of statins and omega-3 supplementation, respectively. The combined meta-analysis of 20 effect sizes showed a significant reduction in LDL-C concentration following administration of statins (WMD, −33.63 mg/dL; 95% CI, −45.77 to −21.49 mg/dL; [Figure A1](#nutrients-12-02218-f0A1){ref-type="fig"}), but not omega-3 supplementation (WMD, 0.12; 95% CI, −0.81 to 1.06 mg/dL; [Figure A1](#nutrients-12-02218-f0A1){ref-type="fig"}). Relationships between cardiovascular event reduction and LDL-C lowering effects by subgroup for statins and omega-3 supplementation are presented in [Figure A2](#nutrients-12-02218-f0A2){ref-type="fig"} and [Figure A3](#nutrients-12-02218-f0A3){ref-type="fig"}. CHD reduction effect of statins (*p* = 0.004) and stroke reduction effect of omega-3 supplementation (*p* = 0.02) were observed to be non-linearly associated with the LDL-C lowering effect, with the explained deviance of over 97%.

The coefficient from the meta-regression model represents the change in the log-transformed relative risk for every increase of one mg/dL in serum lipid concentrations.

3.3. Network Meta-Analysis of Direct and Indirect Estimates {#sec3dot3-nutrients-12-02218}
-----------------------------------------------------------

[Figure 2](#nutrients-12-02218-f002){ref-type="fig"} presents the comparative effects among statins, omega-3 supplementation, and controls with regard to the risk of CVD events. Compared with findings from the meta-analysis of direct evidence, a significant effect of simvastatin (RR = 0.72, 95% CI = 0.56--0.92) on CHD was also observed, whereas the network estimates did not reveal any significant effects of pravastatin (RR = 0.88, 95% CI = 0.76--1.01), simvastatin (RR = 0.82, 95% CI = 0.65--1.03), or omega-3 supplementation (RR = 1.03, 95% CI = 0.91--1.17) on the risk of stroke.

Pravastatin had a significantly lower risk of total CVD (RR = 0.81, 95% CI = 0.72--0.91), CHD (RR = 0.75, 95% CI = 0.60--0.94), and MI (RR = 0.71, 95% CI = 0.55--0.94) than omega-3 supplementation. The risks of total CVD, CHD, MI, and stroke in the atorvastatin group were lower than those in the omega-3 group, with RRs (95% CIs) of 0.80 (0.73--0.88), 0.64 (0.50--0.82), 0.75 (0.60--0.93), and 0.81 (0.66--0.99), respectively. Additionally, the risk of total CVD in the fluvastatin and lovastatin groups was lower than that in the omega-3 group, with RRs (95% CI) of 0.41 (0.18--0.95) and 0.77 (0.63--0.94), respectively.

Among statins, pravastatin, fluvastatin, lovastatin, and atorvastatin were found to be associated with lower risks of total CVD than simvastatin, with RRs (95% CIs) of 0.82 (0.69--0.96), 0.42 (0.18--0.97), 0.78 (0.62--0.98), and 0.81 (0.74--0.89), respectively. The risk of CHD in the atorvastatin group was also 19% lower than that in the simvastatin group (RR = 0.81, 95% CI = 0.73--0.90). Fluvastatin was associated with a higher MI risk than pravastatin, with RR = 2.21 and 95% CI = 1.04--4.69.

Data are presented as the relative risk and 95% confidence interval of row-defined intervention versus column-defined comparison for the risk of different cardiovascular events and with corresponding network plots of available direct comparison. The size of nodes is proportional to the number of studies including the respective treatments. The thickness of the edges is proportional to the mean control group risk for comparisons between control and active treatment groups.

3.4. Publication Bias and Contribution Plot {#sec3dot4-nutrients-12-02218}
-------------------------------------------

Funnel plot asymmetry indicating potential publication bias was not observed for different outcomes of CVD events ([Figure 3](#nutrients-12-02218-f003){ref-type="fig"}). The contribution to mixed estimates and the influence on indirect estimates of direct estimates are presented in [Figure A4](#nutrients-12-02218-f0A4){ref-type="fig"}, [Figure A5](#nutrients-12-02218-f0A5){ref-type="fig"}, [Figure A6](#nutrients-12-02218-f0A6){ref-type="fig"} and [Figure A7](#nutrients-12-02218-f0A7){ref-type="fig"}. Overall, most of the direct comparisons contributed nearly 100% to the same mixed comparisons in terms of total CVD ([Figure A4](#nutrients-12-02218-f0A4){ref-type="fig"}) and CHD outcomes ([Figure A5](#nutrients-12-02218-f0A5){ref-type="fig"}), except for control versus simvastatin. In contrast, approximately half of the direct comparisons did not contribute to the same mixed comparisons in terms of MI ([Figure A6](#nutrients-12-02218-f0A6){ref-type="fig"}) and stroke outcomes ([Figure A7](#nutrients-12-02218-f0A7){ref-type="fig"}).

3.5. Treatment Ranking {#sec3dot5-nutrients-12-02218}
----------------------

Fluvastatin had the highest probability of being the primary intervention for total CVD (85.4%) and stroke (42.2%), whereas atorvastatin and pitavastatin had the highest probabilities in terms of CHD (78.1%) and MI (72.7), respectively ([Table 5](#nutrients-12-02218-t005){ref-type="table"}). The surface under the cumulative ranking curve (SUCRA) values of cumulative ranking probability, which accounts for the uncertainty of spuriously high ranks, suggested better ranks for fluvastatin, atorvastatin, pitavastatin, and rosuvastatin in the prevention of total CVD (0.9), CHD (1.0), MI (0.9), and stroke (0.7).

4. Discussion {#sec4-nutrients-12-02218}
=============

This meta-analysis and NMA of 63 RCTs investigated the effect of statins and omega-3 supplementation as well as their comparative efficacy of for the prevention of cardiovascular events. TG and HDL-C independent effects of total statins and omega-3 supplementation on the prevention of total CVD were observed. Furthermore, the effects of total statins and omega-3 supplementation on CHD, MI, and stroke were independent of the lipid-lowering effects of TC, TG, HDL-C, and LDL-C. Although the RCTs examined diverse populations, the findings were generally consistent for the significant risk reduction associated with statins in total CVD, CHD, MI, and stroke; conversely, a beneficial effect on stroke prevention was not observed for omega-3 supplementation. The findings were generally consistent in separate subgroup analyses of statins and omega-3 supplementation or in combined analyses of statins and omega-3 supplementation in terms of total CVD and CHD. Moreover, evidence was robust according to the Dersimonian--Laird methodology of the random-effects model, which accounts for between-study variability when at least two individual RCTs are included in pooled analysis.

The NMA of 264,516 adults showed that most statins and omega-3 supplementation were effective in reducing total CVD, CHD, and MI risks compared to the control group. Fluvastatin, atorvastatin, pitavastatin, and rosuvastatin were found to have the greatest effects on reducing total CVD, CHD, MI, and stroke, respectively.

Several guidelines have recommended statins for the primary and secondary prevention of CVD \[[@B89-nutrients-12-02218]\]. Statins can be classified as weak statins (simvastatin and pravastatin, compounds found in nature), strong (atorvastatin, pitavastatin, and rosuvastatin, synthetic molecules), and normal (fluvastatin and lovastatin) based on their ability to reduce cholesterol levels \[[@B90-nutrients-12-02218]\]. Yebyo et al. recently investigated the primary prevention effects of specific statins by NMA, though the date of the literature search was restricted to between 2013 and 2018, and the effect on total CVD and CHD was not investigated \[[@B31-nutrients-12-02218]\]. Statins were generally found to be associated with risk reductions in nonfatal MI (RR = 0.62, 95% CI = 0.53--0.72) and nonfatal stroke (RR = 0.83, 95% CI = 0.53--0.72) but not fatal MI or fatal stroke. In the current study, we found that statins significantly lowered the risks of combined fatal and nonfatal MI and stroke.

Several actions of omega-3 that overlap with the mechanisms of the pleiotropic effects of statins, including endothelial function improvement and antioxidant, anti-inflammatory, and antithrombotic effects, have been proposed \[[@B91-nutrients-12-02218],[@B92-nutrients-12-02218]\]. Nonetheless, a previous meta-analysis also demonstrated no significant effects of omega-3 supplementation on total CVD (RR = 0.99, 95% CI = 0.89--1.09) and MI (RR = 0.81, 95% CI = 0.65--1.01) \[[@B93-nutrients-12-02218]\]. Rizos et al. also reported a null result for the effect of omega-3 supplementation on MI (RR = 0.89, 95% CI = 0.76--1.04) \[[@B94-nutrients-12-02218]\]. Aung et al. specified fatal and nonfatal CHD and different types of stroke, and the findings were still non-significant \[[@B28-nutrients-12-02218]\]. In contrast, Hu et al. recently updated findings from large-sample RCTs \[[@B11-nutrients-12-02218]\], including the A Study of Cardiovascular Events in Diabetes (ASCEND) trial \[[@B87-nutrients-12-02218]\], Vitamin D and Omega-3 Trial (VITAL) \[[@B88-nutrients-12-02218]\], and Reduction of Cardiovascular Events in Icosapent Ethyl-Intervention Trial (REDUCE-IT) that omega-3 supplementation significantly reduced the risk of total CVD (RR = 0.95, 95% CI = 0.92--0.98), MI (RR = 0.88, 95% CI = 0.83--0.94), and CHD (RR = 0.93, 95% CI = 0.89--0.96) \[[@B86-nutrients-12-02218]\]. Regardless a null finding for omega-3 supplementation in the prevention of stroke has consistently been reported \[[@B11-nutrients-12-02218],[@B93-nutrients-12-02218],[@B94-nutrients-12-02218]\].

This study had some intrinsic limitations. First, we did not specify the effect of statins and omega-3 supplementation on primary and secondary prevention of event outcomes, and primary prevention may be defined differentially in various studies. For example, Yebyo et al. categorized the population with CVD history was less than 10% of the total sample size as primary prevention \[[@B31-nutrients-12-02218]\], Naci et al. accepted a percentage up to 20% \[[@B22-nutrients-12-02218]\]. Additionally, the time frame in the identification of CVD history differed among RCTs. Therefore, we assumed that the effects of CVD and MI histories as well as other risk factors, such as hypertension, diabetes, and smoking, might not be significant. Second, arm-based data considering the sample size and number of events were included in the final analysis. Although the time to outcome for survival data is important in evaluating the effect of the intervention, the findings were not based on the contrast-based data of relative estimates because the hazard ratio was not available for all outcomes and in all RCTs. Third, there were only a few head-to-head RCTs of a statin versus a statin \[[@B80-nutrients-12-02218],[@B81-nutrients-12-02218],[@B82-nutrients-12-02218],[@B83-nutrients-12-02218],[@B84-nutrients-12-02218],[@B85-nutrients-12-02218]\] and no RCT of a statin versus omega-3 supplementation. Last, due to the limitation of data availability, meta-regression for each type of statin as well as for omega-3 supplementation could not be performed separately.

Despite the abovementioned limitations, this study has important methodological strengths. To our knowledge, this is the first indirect comparison of statins versus omega-3 supplementation borrowing direct evidence of statins versus controls and omega-3 supplementation versus controls to provide quantitative evidence for the prevention of CVD events. The study was designed to minimize heterogeneity among controls from different RCTs. Although Abdelhamid et al. reported comprehensive evidence from 79 RCTs of omega-3 supplementation for the primary and secondary prevention of CVD \[[@B27-nutrients-12-02218]\], several RCTs were excluded from our analysis because of inappropriate control groups. The control group, which was defined as those with a lower intake of omega-3, might inappropriately develop an intermediary association with statins. RCTs in which the control group contained omega-6 were also excluded, as the debated effect of omega-6 intake has been reported \[[@B95-nutrients-12-02218],[@B96-nutrients-12-02218],[@B97-nutrients-12-02218],[@B98-nutrients-12-02218],[@B99-nutrients-12-02218]\]; thus, the inclusion of omega-6 in the control group might underestimate or overestimate the protective effect of omega-3. Moreover, robust findings were obtained by using different models in the meta-analysis and by comparing direct evidence from the meta-analysis and combined evidence from the NMA.

5. Conclusions {#sec5-nutrients-12-02218}
==============

In summary, this study suggests that pravastatin and atorvastatin are more beneficial than omega-3 supplementation in reducing the risk of total CVD, CHD, and MI. Fluvastatin, atorvastatin, pitavastatin, and rosuvastatin showed the greatest effects on reducing total CVD, CHD, MI, and stroke, respectively.
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![Meta-analysis for LDL-C lowering effect of statins and omega-3 supplementation. WMD, weighted mean difference; CI, confidence interval; LDL-C, low-density lipoprotein cholesterol](nutrients-12-02218-g0A1){#nutrients-12-02218-f0A1}

![Non-linear association between cardiovascular event reduction and LDL-C lowering effects of statins. Cardiovascular events include total cardiovascular disease (CVD), coronary heart disease (CHD), myocardial infarction (MI), and stroke. RR, relative risk; CVD, cardiovascular disease; CHD, coronary heart disease; MI, myocardial infarction; LDL-C, low-density lipoprotein cholesterol.](nutrients-12-02218-g0A2){#nutrients-12-02218-f0A2}

![Non-linear association between cardiovascular event reduction and LDL-C lowering effects of omega-3 supplementation. Cardiovascular events include (**a**) total cardiovascular disease (CVD), (**b**) coronary heart disease (CHD), (**c**) myocardial infarction (MI), and (**d**) stroke. RR, relative risk; LDL-C, low-density lipoprotein cholesterol.](nutrients-12-02218-g0A3){#nutrients-12-02218-f0A3}

![Contribution plot for the total cardiovascular disease network. The size of the square is weighted as the percentage (as number) of the contribution of the direct estimate (horizontal axis) to the network estimate (vertical axis).](nutrients-12-02218-g0A4){#nutrients-12-02218-f0A4}

![Contribution plot for the coronary heart disease network. The size of the square is weighted as the percentage (as number) of the contribution of the direct estimate (horizontal axis) to the network estimate (vertical axis).](nutrients-12-02218-g0A5){#nutrients-12-02218-f0A5}

![Contribution plot for the myocardial infarction network. The size of the square is weighted as the percentage (as number) of the contribution of the direct estimate (horizontal axis) to the network estimate (vertical axis).](nutrients-12-02218-g0A6){#nutrients-12-02218-f0A6}

![Contribution plot for the stroke network. The size of the square is weighted as the percentage (as number) of the contribution of the direct estimate (horizontal axis) to the network estimate (vertical axis).](nutrients-12-02218-g0A7){#nutrients-12-02218-f0A7}
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![Network meta-analysis of statin, omega-3, and control in the risk of different cardiovascular events.](nutrients-12-02218-g002){#nutrients-12-02218-f002}

![Funnel plot for publication bias according to (**a**) total cardiovascular disease, (**b**) coronary heart disease, (**c**) myocardial infarction, and (**d**) stroke.](nutrients-12-02218-g003){#nutrients-12-02218-f003}

nutrients-12-02218-t001_Table 1

###### 

Characteristics of trials included in the final analysis.

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study                                                       Age (Years)   Follow-Up (Years)   MI (%)   Hypertension (%)   Diabetes (%)   Smoker (%)   Intervention Arm   Comparison Arm                                                                        
  ----------------------------------------------------------- ------------- ------------------- -------- ------------------ -------------- ------------ ------------------ ---------------- ------ ----- ----- ----- -------------- -------- ------ ------ ----- -----
  Manson 2019 (VITAL) \[[@B88-nutrients-12-02218]\]           67.1          5.3                          49.8               13.7           7.2          EPA+DHA            12,933           308    145   148   527   Control        12,938   370    200    142   567

  Bhatt 2019 (REDUCE-IT) \[[@B86-nutrients-12-02218]\]        64            4.9                                             58.6                        Icosapent Ethyl    4069                    250               Control        4090            355          

  Bowman 2018 (ASCEND) \[[@B87-nutrients-12-02218]\]          63.3          7.4                 0        49.4               100            53.8         EPA+DHA            7740                    186   252         Control        7740            200    251   

  Yusuf 2016\                                                 63.8          5.6                 0        37.9               5.8            27.7         Rosuvastatin       6361                    105   45    70    Control        6344            140    69    99
  (HOPE-3) \[[@B71-nutrients-12-02218]\]                                                                                                                                                                                                                         

  Ford 2016 (WOSCOPS) \[[@B33-nutrients-12-02218]\]           55            4.9                 0                                          44           Pravastatin        3302                                194   Control        3293                         223

  Izawa 2015\                                                 66            2                                                              63.2         Pravastatin        253                                 5     Atorvastatin   255                          1
  (ALPS-AMI) \[[@B82-nutrients-12-02218]\]                                                                                                                                                                                                                       

  Hosomi 2015\                                                              4.9                          76                 23.4           53.6         Pravastatin        780                           5           Control        785                    12    
  (J-STAR) \[[@B32-nutrients-12-02218]\]                                                                                                                                                                                                                         

  Bonds 2014\                                                 74            4.8                 7        5.9                13             56.6         EPA+DHA            2147             183    28    28    48    Control        2056     187    30     30    41
  (AREDS2) \[[@B79-nutrients-12-02218]\]                                                                                                                                                                                                                         

  Takano 2013\                                                62.6          3                   25.1     45.3               27.4                        Pitavastatin       288                           3     8     Control        286                    8     9
  (PEARL) \[[@B43-nutrients-12-02218]\]                                                                                                                                                                                                                          

  Roncaglioni 2013\                                           64            5                            84.6               59.9           21.7         EPA+DHA            6239             620    310   80    80    Control        6266     630    324    90    60
  (Risk & Prevention) \[[@B52-nutrients-12-02218]\]                                                                                                                                                                                                              

  Macchia 2013\                                               66.1                                       91.4               12.9           42.2         EPA+DHA            289              4            1     3     Control        297      4             1     3
  (FORWARD) \[[@B14-nutrients-12-02218]\]                                                                                                                                                                                                                        

  Yakusevich 2012 \[[@B35-nutrients-12-02218]\]               65.7          1                   9.8      77.6               9.8                         Simvastatin        86                            4     5     Control        97                     5     7

  Bosch 2012\                                                 63.5          6.2                          79.5                              12.4         EPA+DHA            6281             2055         344   314   Control        6255     2087          316   336
  (ORIGIN) \[[@B75-nutrients-12-02218]\]                                                                                                                                                                                                                         

  Nicholls 2011\                                              57.6          2                   24.4     70.4               15.3           32.3         Atorvastatin       519                           11    2     Rosuvastatin   520                    11    3
  (SATURN) \[[@B83-nutrients-12-02218]\]                                                                                                                                                                                                                         

  Emberson 2011\                                              64            5                   43.5                        30.4           74.8         Simvastatin        10,269                              444   Control        10,267                       585
  (MRC/BHF) \[[@B70-nutrients-12-02218]\]                                                                                                                                                                                                                        

  Ostadal 2010\                                               62.1          1                   7.7      51.3               19.2           29.2         Fluvastatin        78               10           2     1     Control        78       21            4     3
  (FACS) \[[@B62-nutrients-12-02218]\]                                                                                                                                                                                                                           

  Kromhout 2010\                                              69            3.4                 100      89.7               21             16.9         EPA+DHA            2404             170    122   89    11    Control        2433     185    132    102   10
  (AlphaOmega) \[[@B60-nutrients-12-02218]\]                                                                                                                                                                                                                     

  Galan 2010\                                                 61.4          4.7                 46                                         72.8         EPA+DHA            1253             81     51    32    29    Control        1248     76     53     28    28
  (SU.FOL.OM3) \[[@B67-nutrients-12-02218]\]                                                                                                                                                                                                                     

  Einvik 2010\                                                70            3                            28                 14.5           34           EPA+DHA            282              32     11    11          Control        281      36     9      9     
  (DO IT) \[[@B66-nutrients-12-02218]\]                                                                                                                                                                                                                          

  Dangour 2010\                                               75            2                   3.9      55.9                                           EPA+DHA            434                                 7     Control        433                          8
  (OPAL) \[[@B13-nutrients-12-02218]\]                                                                                                                                                                                                                           

  Chan 2010\                                                  58            3.5                                                            48.3         Rosuvastatin       134              35                       Control        135      44                  
  (ASTRONOMER) \[[@B34-nutrients-12-02218]\]                                                                                                                                                                                                                     

  Rauch 2009\                                                 64            1                   14.4     66.5               27             36.7         EPA+DHA            1919             199    547   87    27    Control        1885     165    568    78    13
  (OMEGA) \[[@B53-nutrients-12-02218]\]                                                                                                                                                                                                                          

  Mok 2009\                                                   63            2                            69.2               91.2           26.4         Simvastatin        113                     2                 Control        114             3            
  (RCASS) \[[@B65-nutrients-12-02218]\]                                                                                                                                                                                                                          

  Fellstrom 2009\                                             64.2          3.8                 10.2                        26.4           15.5         Rosuvastatin       1389                          91    53    Control        1384                   107   45
  (AURORA) \[[@B33-nutrients-12-02218]\]                                                                                                                                                                                                                         

  Tavazzi 2008\                                               68            3.9                 14.2     54.6               28.3           14.2         EPA+DHA            3494             1635         107   122   Control        3481     1687          129   103
  (GISSI-HF) \[[@B45-nutrients-12-02218]\]                                                                                                                                                                                                                       

  Tavazzi 2008\                                               68            3.9                          54.3                              14.1         Atorvastatin       2285                          61    82    Control        2289                   70    66
  (GISSI-HF) \[[@B37-nutrients-12-02218]\]                                                                                                                                                                                                                       

  Ridker 2008\                                                66            1.9                 0                                          15.8         Rosuvastatin       8901                          31    33    Control        8901                   69    64
  (JUPITER) \[[@B47-nutrients-12-02218]\]                                                                                                                                                                                                                        

  Yokoyama 2007 (JELIS) \[[@B36-nutrients-12-02218]\]         61            4.6                 5.6      35.5               16.3           18.9         EPA                9326                    262   71    166   Control        9319            324    93    162

  Kjekshus 2007 (CORONA) \[[@B55-nutrients-12-02218]\]        73            2.7                 60       63                 29.5           8.6          Rosuvastatin       2514                          131   126   Control        2497                   154   138

  Deedwania 2007 (SAGE) \[[@B81-nutrients-12-02218]\]         72.5          1                   45.9     64.5               23.2           59.4         Atorvastatin       446                           16    1     Pravastatin    445                    16    3

  Nakamura 2006 (MEGA) \[[@B63-nutrients-12-02218]\]          58.3          5.3                          41.8               20.8           20.6         Pravastatin        3866             125    66    17    50    Control        3966     172    101    33    62

  Knopp 2006 (ASPEN) \[[@B59-nutrients-12-02218]\]            61            4                   16.4     55.1               100            12.4         Atorvastatin       1211                          297         Control        1199                   313   

  Brouwer 2006 (SOFA) \[[@B12-nutrients-12-02218]\]           61.5          1                   62.6     50.7               15.9           67           EPA+DHA            273              65     1                 Control        273      62     3            

  Amarenco 2006 (SPARCL) \[[@B77-nutrients-12-02218]\]        62.7          4.9                                                            59           Atorvastatin       2365             530    123   43    265   Control        2366     687    204    82    311

  Yokoi 2005 (ATHEROMA) \[[@B40-nutrients-12-02218]\]         59.3          3                   45.5     42                 18.8                        Pravastatin        142              23           2     5     Control        146      25            4     4

  Wanner 2005 \[[@B41-nutrients-12-02218]\]                   65.7          4                   17.6                        100            40.4         Atorvastatin       619              205          93    60    Control        636      246           112   45

  Stone 2005 \[[@B42-nutrients-12-02218]\]                                  1                   38.9     62.4               16.5           69.5         Atorvastatin       96                            1           Control        103                    1     

  Raitt 2005 \[[@B16-nutrients-12-02218]\]                    62.5          2                   55.5     50.5                                           EPA+DHA            100              2      1     1           Control        100      5      3      3     

  Pedersen 2005 (IDEAL) \[[@B85-nutrients-12-02218]\]         61.7          4.8                 28       58.4               12             79.1         Atorvastatin       4439             1176   898   267   151   Simvastatin    4449     1370   1059   321   174

  Makuuchi 2005 (PCABG) \[[@B54-nutrients-12-02218]\]         58.9          4.5                 62       51.5               33.3           41.9         Pravastatin        152              26           1     4     Control        151      36            4     3

  Sever 2004 (ASCOT-LLA) \[[@B46-nutrients-12-02218]\]        63            5                            100                24.6           32.7         Atorvastatin       5168             389                89    Control        5137     486                 121

  Nissen 2004 (REVERSAL) \[[@B84-nutrients-12-02218]\]        56.2          1.5                          68.5               18.9           26.3         Atorvastatin       253                           4     1     Pravastatin    249                    7     1

  Nakagawa 2004 (PCS) \[[@B64-nutrients-12-02218]\]           55            5.4                          59.2               17.5           67.5         Pravastatin        54               13           2     3     Control        66       19            3     4

  Koren 2004 (ALLIANCE) \[[@B58-nutrients-12-02218]\]         61.2          4.5                 57.8                        22.1           19.5         Atorvastatin       1217             408          52    35    Control        1225     443           94    39

  Colhoun 2004 (CARDS) \[[@B74-nutrients-12-02218]\]          62            3.9                                             100            65.3         Atorvastatin       1428                                21    Control        1410                         39

  Cannon 2004 (PROVE IT-TIMI) \[[@B80-nutrients-12-02218]\]   58.2          2                   18.5     50.2               17.6                        Atorvastatin       2099                          139   21    Pravastatin    2063                   153   21

  Shepherd 2002 (PROSPER) \[[@B49-nutrients-12-02218]\]       75.3          3.2                 13.4     61.9               10.7           26.8         Pravastatin        2891             454    77          135   Control        2913     523    102          131

  Serruys 2002\                                               60            3.9                 44.4     38.6               12             71.5         Fluvastatin        844                                 2     Control        833                          1
  (LIPS) \[[@B50-nutrients-12-02218]\]                                                                                                                                                                                                                           

  Sawayama 2002 (FAST) \[[@B51-nutrients-12-02218]\]          66.3          2                            39.6               25             57.8         Pravastatin        83               4            4           Control        81       11            11    

  Liem 2002 (FLORIDA) \[[@B56-nutrients-12-02218]\]           60.5          1                   11.5                                                    Fluvastatin        265                           21          Control        275                    13    

  Davis 2002 (ALLHAT-LTT) \[[@B73-nutrients-12-02218]\]       66.4          4.8                                             35.1           23.2         Pravastatin        5170                                209   Control        5185                         231

  Arthros 2002 (GREACE) \[[@B78-nutrients-12-02218]\]         58.5          3                   81.2     42.9               19.6                        Atorvastatin       800                           21    9     Control        800                    51    17

  Nilsen 2001 \[[@B15-nutrients-12-02218]\]                   64            1.5                 23.3     24.3               10.3           75.7         EPA+DHA            150              42           17          Control        150      36            12    

  Teo 2000\                                                   61            4                   70       36                 11             82           Simvastatin        230                           11    4     Control        230                    10    7
  (SCAT) \[[@B39-nutrients-12-02218]\]                                                                                                                                                                                                                           

  Valagussa 1999 (GISSI-P) \[[@B44-nutrients-12-02218]\]      59.4          3.5                 12       35.6               14.8           77.2         EPA+DHA            2836                                44    Control        2828                         41

  Riegger 1999 \[[@B48-nutrients-12-02218]\]                  59.8          1                   35.6     29.3               5.5            9.6          Fluvastatin        187                                       Control        178                          

  Plehn 1999\                                                               5                   100      42.7               14.1           16.1         Pravastatin        2081                                92    Control        2078                         124
  (CARE) \[[@B57-nutrients-12-02218]\]                                                                                                                                                                                                                           

  Tonkin 1998\                                                62            6.1                          41.7               8.7            73.3         Pravastatin        4512                          336   169   Control        4502                   463   204
  (LIPID) \[[@B38-nutrients-12-02218]\]                                                                                                                                                                                                                          

  Downs 1998 (AFCAPS/TexCAPS) \[[@B72-nutrients-12-02218]\]   58            5.2                          21.9               2.3            12.4         Lovastatin         3304             194    163   57          Control        3301     255    215    95    

  Bestehorn 1997 (CIS) \[[@B76-nutrients-12-02218]\]          49.8          2.3                                                            84.3         Simvastatin        129                           1           Control        125                    5     

  Jukema 1995 (REGRESS) \[[@B61-nutrients-12-02218]\]         56            2                   47.4     27.8               0.1            88           Pravastatin        450              59                       Control        434      93                  

  Furberg 1995 (PLAC-I & II) \[[@B68-nutrients-12-02218]\]    58            3                   48.5     40.5               0.7            15.5         Pravastatin        281                     14    9           Control        278             29     24    

  Furberg 1994 (ACAPS) \[[@B69-nutrients-12-02218]\]          62            2.8                          28.8                              56.5         Lovastatin         460                           5           Control        459                    5     
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

CVD, cardiovascular disease; CHD, coronary heart disease; MI, myocardial infarction; EPA, eicosapentaenoic acid; and DHA, docosahexaenoic acid.

nutrients-12-02218-t002_Table 2

###### 

Lipid profiles of study participants.

  Study                                                                Baseline Measurement   Change Difference                                                                        
  -------------------------------------------------------------------- ---------------------- ------------------- ------ ------- ------- ------- ------ ------- ------- ------- ------ -------
  Manson 2019 (VITAL) \[[@B88-nutrients-12-02218]\]                                                                                                                                    
  Bhatt 2019 (REDUCE-IT) \[[@B86-nutrients-12-02218]\]                                        216.5               40.0   74.0            216.0   40.0   76.0            −32.5   0      −5.0
  Bowman 2018 (ASCEND) \[[@B87-nutrients-12-02218]\]                                                                                                                                   
  Yusuf 2016 (HOPE-3) \[[@B71-nutrients-12-02218]\]                    201.5                  128.8               44.7   127.8   201.3   126.5   44.9   127.9           −21.2          −34.6
  Ford 2016 (WOSCOPS) \[[@B33-nutrients-12-02218]\]                    272.0                  162.0               44.0   192.0   272.0   164.0   44.0   192.0                          
  Izawa 2015 (ALPS-AMI) \[[@B82-nutrients-12-02218]\]                  204.1                  142.9               47.6   130.2   203.2   130.8   48.0   131.0                   −0.6   
  Hosomi 2015 (J-STAR) \[[@B32-nutrients-12-02218]\]                   210.8                  142.6               53.8   129.5   209.6   141.7   53.0   129.5   −23.2   −9.7    0.8    −21.3
  Bonds 2014 (AREDS2) \[[@B79-nutrients-12-02218]\]                                                                                                                                    
  Takano 2013 (PEARL) \[[@B43-nutrients-12-02218]\]                    203.2                                      50.7   125.2   201.2           50.8   125.5                   2.0    −31.5
  Roncaglioni 2013 (Risk & Prevention) \[[@B52-nutrients-12-02218]\]   215.6                  150.0               50.9   131.8   216.4   150.0   51.2   132.5   −0.5    −8.1    0.6    −0.4
  Macchia 2013 (FORWARD) \[[@B14-nutrients-12-02218]\]                                                                                                                                 
  Yakusevich 2012 \[[@B35-nutrients-12-02218]\]                        211.5                  102.7                      85.1    201.9   91.2           86.2    −29.4   −11.5          8.9
  Bosch 2012 (ORIGIN) \[[@B75-nutrients-12-02218]\]                    189.0                                      46.0   112.0   190.0           46.0   112.0   −1.1    −14.5   0.1    0.6
  Nicholls 2011 (SATURN) \[[@B83-nutrients-12-02218]\]                 193.5                  130.0               44.7   119.9   144.1   110.0   48.6   70.2    −44.7   −30.0   2.1    −42.1
  Emberson 2011 (MRC/BHF) \[[@B70-nutrients-12-02218]\]                                                                                                                                −32.9
  Ostadal 2010 (FACS) \[[@B62-nutrients-12-02218]\]                    212.7                                                     208.8                          −56.2                  
  Kromhout 2010 (AlphaOmega) \[[@B60-nutrients-12-02218]\]             182.5                  145.3               49.9   110.2   182.9   147.9   49.5   110.2                          
  Galan 2010 (SU.FOL.OM3) \[[@B67-nutrients-12-02218]\]                174.0                  106.3               46.4   104.4   175.9   106.3   46.4   102.5                          
  Einvik 2010 (DO IT) \[[@B66-nutrients-12-02218]\]                    243.6                  150.6               54.1   158.1   239.8   150.6   54.1   154.7                          
  Dangour 2010 (OPAL) \[[@B13-nutrients-12-02218]\]                                                                                                                                    
  Chan 2010 (ASTRONOMER) \[[@B34-nutrients-12-02218]\]                 206.1                  108.9               61.5   123.0   203.8   116.9   59.9   120.6                   1.9    −66.9
  Rauch 2009 (OMEGA) \[[@B53-nutrients-12-02218]\]                                                                                                                                     
  Mok 2009 (RCASS) \[[@B65-nutrients-12-02218]\]                       226.2                  118.7               45.6   151.6   227.0   125.8   44.9   150.4   −54.5   −11.5          −50.7
  Fellstrom 2009 (AURORA) \[[@B33-nutrients-12-02218]\]                176.0                  157.0               45.0   100.0   174.0   154.0   45.0   99.0    −46     −24.2   0      −40.1
  Tavazzi 2008 (GISSI-HF) \[[@B45-nutrients-12-02218]\]                                                                                                                                
  Tavazzi 2008 (GISSI-HF) \[[@B37-nutrients-12-02218]\]                                                                  122.2                          121.0                          −0.1
  Ridker 2008 (JUPITER) \[[@B47-nutrients-12-02218]\]                  186.0                  118.0               49.0   108.0   185.0   118.0   49.0   108.0           −19.0   0      −54.0
  Yokoyama 2007 (JELIS) \[[@B36-nutrients-12-02218]\]                  274.9                  153.2               58.8   181.4   274.9   154.1   58.4   181.7   0       −7.6           0
  Kjekshus 2007 (CORONA) \[[@B55-nutrients-12-02218]\]                                        178.0               48.0   137.0           176.0   47.0   136.0           −42.0   2.0    −63.0
  Deedwania 2007 (SAGE) \[[@B81-nutrients-12-02218]\]                  225.8                  164.4               45.5   147.5   221.9   157.1   46.4   144.0   −18.3   −19.3   −2.6   −23.0
  Nakamura 2006 (MEGA) \[[@B63-nutrients-12-02218]\]                   242.5                  127.5               57.6   156.6   242.5   127.5   57.6   156.6   −20.5   −14.2   19.3   −20.7
  Knopp 2006 (ASPEN) \[[@B59-nutrients-12-02218]\]                     194.0                  147.0               47.0   113.0   194.0   145.0   47.0   114.0   −35.5   −20.2   1.1    −33.0
  Brouwer 2006 (SOFA) \[[@B12-nutrients-12-02218]\]                                                                                                                                    
  Amarenco 2006 (SPARCL) \[[@B77-nutrients-12-02218]\]                 211.4                  144.2               50.0   132.7   212.3   143.2   50.0   133.7   −60.3   −34.5   1.1    −54.6
  Yokoi 2005 (ATHEROMA) \[[@B40-nutrients-12-02218]\]                  226.2                  181.1               49.1   143.3   224.8   167.1   50.0   142.0   −27.8   −14.2   0.5    −26.7
  Wanner 2005 \[[@B41-nutrients-12-02218]\]                            218.0                  261.0               36.0   127.0   220.0   267.0   36.0   125.0                          −50.0
  Stone 2005 \[[@B42-nutrients-12-02218]\]                             228.0                  149.0               44.0   149.0   230.0   151.0   43.0   151.0                          −35.9
  Raitt 2005 \[[@B16-nutrients-12-02218]\]                                                                                                                                             
  Pedersen 2005 (IDEAL) \[[@B85-nutrients-12-02218]\]                  196.8                  151.1               46.0   121.6   195.9   146.6   46.1   121.4   −24.3   −23.2   −0.4   −20.0
  Makuuchi 2005 (PCABG) \[[@B54-nutrients-12-02218]\]                  213.7                  166.3               41.4   141.4   214.4   154.2   41.3   141.1   −29.3   −30.5   2.4    −20.3
  Sever 2004 (ASCOT-LLA) \[[@B46-nutrients-12-02218]\]                 211.9                  147.0               50.7   133.0   211.9   146.1   50.7   133.0   −38.7   −18.6   0.8    0
  Nissen 2004 (REVERSAL) \[[@B84-nutrients-12-02218]\]                 231.8                  197.2               42.3   150.2   232.6   197.7   42.9   150.2   −35.4   −16.9   −0.9   −31.5
  Nakagawa 2004 (PCS) \[[@B64-nutrients-12-02218]\]                    200.1                  141.9               43.0   128.7   200.5   143.9   43.3   128.3   −17     −7.9    0.4    −15.3
  Koren 2004 (ALLIANCE) \[[@B58-nutrients-12-02218]\]                  226.0                  197.0               40.0   147.0   225.0   198.0   41.0   146.0   −20.0   −12.0   0      −16.0
  Colhoun 2004 (CARDS) \[[@B74-nutrients-12-02218]\]                   207.3                  150.6               53.8   117.6   206.9   147.9   54.9   116.8   −45.3   −28.4   2.3    −39.9
  Cannon 2004 (PROVE IT-TIMI) \[[@B80-nutrients-12-02218]\]            181.0                  158.0               38.0   106.0   180.0   154.0   39.0   106.0                   0.3    −33.0
  Shepherd 2002 (PROSPER) \[[@B49-nutrients-12-02218]\]                220.4                  132.9               50.3   146.9   220.4   132.9   50.3   146.9                          −34.8
  Serruys 2002 (LIPS) \[[@B50-nutrients-12-02218]\]                    200.0                  160.0               38.0   131.0   199.0   160.0   37.0   132.0   −1.0    0       0.3    −49.9
  Sawayama 2002 (FAST) \[[@B51-nutrients-12-02218]\]                   251.5                  168.7               56.7   160.7   255.2   135.8   56.5   171.6   −1.8            15.3   −43.1
  Liem 2002 (FLORIDA) \[[@B56-nutrients-12-02218]\]                    204.9                  150.6               46.4   135.3   208.8   141.7   46.4   139.2   −45.4   −29.2   1.8    −40.9
  Davis 2002 (ALLHAT-LTT) \[[@B73-nutrients-12-02218]\]                223.7                  150.6               47.6   145.6   223.7   152.8   47.4   145.5   −18.9   0.2     3.4    −17.3
  Arthros 2002 (GREACE) \[[@B78-nutrients-12-02218]\]                  257.0                  184.0               39.0   180.0   255.0   178.0   39.0   179.0   −82.0   −56.0   2.0    −73.0
  Nilsen 2001 \[[@B15-nutrients-12-02218]\]                            229.7                  145.3               41.8           231.6   137.3   44.9           −11.3   −52.9   4.8    
  Teo 2000 (SCAT) \[[@B39-nutrients-12-02218]\]                        202.2                  163.9               38.3   131.1   198.4   156.8   37.5   128.8   −48.0   −31.9   1.9    −44.1
  Valagussa 1999 (GISSI-P) \[[@B44-nutrients-12-02218]\]               210.2                  162.6               41.5   137.3   211.6   161.9   41.7   138.5   2.6     −6.3    −0.2   4.2
  Riegger 1999 \[[@B48-nutrients-12-02218]\]                           289.0                  189.0               53.0   198.0   284.0   183.0   56.0   193.0   −36.4                  −37.9
  Plehn 1999 (CARE) \[[@B57-nutrients-12-02218]\]                      209.0                  156.0               39.0   139.0   209.0   155.0   39.0   139.0   42.0    22.0    −2.0   44.0
  Tonkin 1998 (LIPID) \[[@B38-nutrients-12-02218]\]                    218.0                  142.0               36.0   150.0   218.0   138.0   36.0   150.0                          
  Downs 1998 (AFCAPS/TexCAPS) \[[@B72-nutrients-12-02218]\]            225.4                  168.2               36.8   153.3   209.2   166.8   37.5   153.6   −60.3   −29.0   1.7    −40.6
  Bestehorn 1997 (CIS) \[[@B76-nutrients-12-02218]\]                   240.3                                      44.3   164.5   243.4           43.6   167.4                          
  Jukema 1995 (REGRESS) \[[@B61-nutrients-12-02218]\]                  232.8                  156.8               36.0   166.3   234.0   159.4   36.0   166.7   −45.2   −19.5   3.1    −44.5
  Furberg 1995 (PLAC-I & II) \[[@B68-nutrients-12-02218]\]             232.0                  166.0               41.0   165.0   230.0   169.0   41.0   162.0                          
  Furberg 1994 (ACAPS) \[[@B69-nutrients-12-02218]\]                   235.2                                      51.7   156.5   235.3           52.2   154.6                          

CVD, cardiovascular disease; CHD, coronary heart disease; MI, myocardial infarction; EPA, eicosapentaenoic acid; DHA, docosahexaenoic acid; TC, total cholesterol; TG, triglyceride; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol. Data are presented as the mean or median serum lipid concentration. Change difference is defined as difference between lipid changes in the intervention arm versus lipid changes in the comparison arm. Change difference = (achieved level---baseline level) ~intervention\ arm~---(achieved level---baseline level) ~comparison\ arm~.

nutrients-12-02218-t003_Table 3

###### 

Pooled relative risk and 95% confidence interval from meta-analyses.

                                         *N* (I^2^)   Fixed-Effects Model   Random-Effects Model
  -------------------------------------- ------------ --------------------- ----------------------
  **Total cardiovascular** **disease**                                      
  Statins                                14 (30.0%)   0.81 (0.78--0.85)     0.81 (0.76--0.86)
  Atorvastatin                           4 (55.5%)    0.83 (0.78--0.88)     0.83 (0.76--0.91)
  Fluvastatin                            1 (NA)       0.48 (0.24--0.94)     0.48 (0.24--0.94)
  Lovastatin                             1 (NA)       0.76 (0.63--0.91)     0.76 (0.63--0.91)
  Pravastatin                            7 (28.8%)    0.81 (0.74--0.89)     0.77 (0.67--0.89)
  Rosuvastatin                           1 (NA)       0.80 (0.55--1.16)     0.80 (0.55--1.16)
  Omega-3                                13 (0%)      0.98 (0.95--1.01)     0.98 (0.95--1.01)
  Overall                                27 (59.6%)   0.92 (0.90--0.94)     0.89 (0.85--0.94)
  **Coronary heart disease**                                                
  Statins                                7 (0%)       0.69 (0.62--0.77)     0.70 (0.62--0.77)
  Atorvastatin                           1 (NA)       0.60 (0.49--0.75)     0.60 (0.49--0.75)
  Lovastatin                             1 (NA)       0.76 (0.62--0.92)     0.76 (0.62--0.92)
  Pravastatin                            3 (0%)       0.69 (0.56--0.84)     0.69 (0.56--0.84)
  Rosuvastatin                           1 (NA)       0.75 (0.58--0.96)     0.75 (0.58--0.96)
  Simvastatin                            1 (NA)       0.67 (0.11--3.95)     0.67 (0.11--3.95)
  Omega-3                                10 (0%)      0.90 (0.84--0.96)     0.90 (0.85--0.96)
  Overall                                17 (44.6%)   0.84 (0.79--0.88)     0.81 (0.75--0.89)
  **Myoca** **rdial infarction**                                            
  Statins                                27 (51.4%)   0.74 (0.69--0.79)     0.69 (0.61--0.78)
  Atorvastatin                           7 (73.6%)    0.79 (0.71--0.87)     0.70 (0.55--0.89)
  Fluvastatin                            2 (42.6%)    1.40 (0.76--2.56)     1.18 (0.40--3.46)
  Lovastatin                             2 (0%)       0.62 (0.45--0.85)     0.62 (0.45--0.85)
  Pitavastatin                           1 (NA)       0.37 (0.10--1.39)     0.37 (0.10--1.39)
  Pravastatin                            8 (3.1%)     0.68 (0.60--0.77)     0.66 (0.56--0.78)
  Rosuvastatin                           4 (62.9%)    0.74 (0.64--0.86)     0.71 (0.55--0.91)
  Simvastatin                            3 (11.2%)    0.82 (0.43--1.56)     0.85 (0.41--1.78)
  Omega-3                                15 (45.6%)   0.88 (0.82--0.94)     0.89 (0.80--0.99)
  Overall                                42 (53.8%)   0.81 (0.77--0.85)     0.78 (0.72--0.85)
  **Stroke**                                                                
  Statins                                26 (33.3%)   0.84 (0.80--0.89)     0.85 (0.79--0.92)
  Atorvastatin                           7 (64.9%)    0.88 (0.79--0.98)     0.88 (0.71--1.10)
  Fluvastatin                            2 (11.4%)    0.75 (0.17--3.31)     0.77 (0.13--4.38)
  Pravastatin                            9 (0%)       0.88 (0.80--0.96)     0.88 (0.80--0.96)
  Rosuvastatin                           4 (68.8%)    0.81 (0.70--0.95)     0.80 (0.60--1.07)
  Simvastatin                            3 (0%)       0.76 (0.67--0.85)     0.76 (0.67--0.85)
  Omega-3                                13 (36.1%)   1.02 (0.94--1.10)     0.88 (0.71--1.10)
  Overall                                39 (46.2%)   0.90 (0.86--0.94)     0.91 (0.85--0.98)
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###### 

Change difference in lipid profiles in the association with risk reduction of cardiovascular events.

  Covariate   Total Cardiovascular Disease   Coronary Heart Disease   Myocardial Infarction   Stroke                              
  ----------- ------------------------------ ------------------------ ----------------------- -------- --------- ------ --------- ------
  TC          0.0046                         \<0.001                  0.0042                  0.047    0.0055    0.08   −0.0111   0.53
  TG          0.0026                         0.51                     0.0098                  0.004    0.0009    0.89   −0.0117   0.67
  HDL-C       −0.0116                        0.18                     −0.0065                 0.64     −0.0198   0.35   0.0480    0.67
  LDL-C       0.0034                         0.004                    0.0044                  0.048    0.0048    0.09   −0.0126   0.36

TC, total cholesterol; TG, triglyceride; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol.

nutrients-12-02218-t005_Table 5

###### 

Ranking probabilities and surface under the cumulative ranking (SUCRA) values of treatments according to different outcomes.

                                         1st    2nd    3rd    4th    5th    6th    7th    8th    9th    SUCRA
  -------------------------------------- ------ ------ ------ ------ ------ ------ ------ ------ ------ -------
  **Total cardiovascular** **disease**                                                                  
  Control                                0      0      0      0      0.3    5.3    33.2   61.3          0.1
  Omega-3                                0      0      0      0.2    7.5    43.3   44.3   4.7           0.2
  Simvastatin                            0      0      0.1    0.8    13.2   45.5   19.6   20.7          0.2
  Pravastatin                            0.7    11.4   27.2   34.6   25.8   0.3    0      0             0.6
  Fluvastatin                            85.4   7.1    1.7    1.5    2.1    0.6    0.3    1.3           0.9
  Lovastatin                             3.6    32.0   30.1   17.5   15.6   1.0    0.2    0.1           0.7
  Atorvastatin                           0.7    11.3   31.5   37.5   19.0   0      0      0             0.6
  Rosuvastatin                           9.7    38.3   9.5    7.9    16.5   3.9    2.4    11.9          0.6
  **Coronary heart disease**                                                                            
  Control                                0      0      0      0      0      2.5    97.5                 0
  Omega-3                                0      0      0.1    1.2    14.8   83.3   0.7                  0.2
  Simvastatin                            0      26.8   26.1   24.6   18.8   3.4    0.3                  0.6
  Pravastatin                            13.3   31.6   28.0   17.9   8.8    0.4    0                    0.7
  Lovastatin                             3.2    12.3   21.7   29.5   29.1   3.9    0.3                  0.5
  Atorvastatin                           78.1   15.9   4.9    1.2    0      0      0                    1
  Rosuvastatin                           5.4    13.5   19.4   25.6   28.6   6.4    1.2                  0.5
  **Myocardial infarction**                                                                             
  Control                                0      0      0      0      0.1    1.4    18.8   66.5   13.2   0.1
  Omega-3                                0      0      0.1    0.8    7.4    33.0   49.5   8.5    0.7    0.3
  Simvastatin                            1.0    3.7    5.8    10.1   18.0   29.2   17.4   11.6   3.3    0.4
  Pravastatin                            8.4    30.1   28.2   19.0   10.6   3.3    0.4    0      0      0.7
  Fluvastatin                            0.2    0.8    0.7    0.9    2.0    3.6    5.4    7.4    78.9   0.1
  Lovastatin                             13.3   32.8   13.5   12.0   13.4   9.3    3.7    1.8    0.3    0.7
  Atorvastatin                           2.8    16.0   30.9   30.9   16.5   2.7    0.2    0      0      0.7
  Pitavastatin                           72.7   6.0    2.9    2.7    3.5    3.0    2.1    4.0    3.6    0.9
  Rosuvastatin                           2.1    10.6   17.9   23.6   28.5   14.4   2.6    0.3    0      0.6
  **Stroke**                                                                                            
  Control                                0      0      0.1    1.2    13.3   38.1   37.2   10.1          0.2
  Omega-3                                0      0      0.4    2.3    8.0    21.7   39.6   28.0          0.2
  Simvastatin                            10.9   23.4   23.1   19.5   13.0   6.6    2.4    1.1           0.7
  Pravastatin                            1.9    8.0    16.8   27.3   28.2   14.7   2.2    0.7           0.5
  Fluvastatin                            42.2   8.2    2.9    2.6    3.4    3.0    6.1    31.5          0.6
  Atorvastatin                           5.5    18.2   28.3   25.2   16.3   5.6    0.6    0.2           0.6
  Pitavastatin                           25.9   15.5   4.6    4.7    5.5    5.2    10.6   28.0          0.5
  Rosuvastatin                           13.5   26.6   23.7   17.1   12.3   5.2    1.2    0.4           0.7
